Table 4 : Correlation of DNA-ploidywith recurrence-free survival time.


  Year Journal Number of
patients
Months
follow-up
Significance p Flow/Image
cytometry
Comment

After RPE

Oxford level 2b

Bantis et al., [175] 2009 Tumori 112 60 0.001 ICM pT2a-c, pT3a
Pretorius et al., [16] 2009 Cell Oncol 186 73.3 GS 7<0.001 ICM --
Bantis et al., [176] 2005 J Exp Clin Cancer Res 70 60.,0 <0.007 ICM --
Deliveliotis et al., [177] 2003 World J Urol 84 45 0.0074 FCM --
Amling et al., [178] 1999 J Urol 106 120 0.002 FCM After salvage prostatectomy
Gettman et al., [179] 1999 Adult Urology 211 60 <0.001 FCM --
Mora et al., [180] 1999 Cancer Control 65 80 0.002 FCM --
Lerner et al., [181] 1996 J Urol 904 38.4 p 0.0089 FCM pT1, pT2
Zincke et al., [182] 1992 Cancer 370 60 0.0008 FCM Plus hormonal treatment
Wirth et al., [183] 1991 Eur Urol 80 120 0.00013 FCM pT 1-3
Nativ et al., [184] 1989 Mayo Clin Proc 146 94.8 0.006 FCM Stage C n=146
Blute et al., [185] 1989 J Urol 315 96 0.0004 FCM Stages A, B
Winkler et al., [186] 1988 Mayo Clin Proc 91 90 0.001 FCM Low and high GS

Oxford level 3b

Hawkins et al., [187] 1995 Urology 894 100 <0.05 FCM Partially HAT, & radiation
Carmichael et al., [188] 1995 J Urol 112 102 <0.034 FCM T2, NO, GS <=6
Voges et al., [189] 1993 Eur Urol 85 35 <0.005 FCM <8 ccm & <30% GS 4/5
Montgomery et al., [190] 1990 Arch Surg 261 240 <0.001 FCM Stage B
Lee et al., [191] 1988 J Urol 88 60 <0.001 FCM Interval free of disease

Oxford level 4

Veltri et al., [192] 1994 J Cell Biochem 124 103.2 0.008 ICM PSA-recurrence

After external radiation

Oxford level 2b

Centeno et al., [193] 1994 Int J Rad Oncol Biol
Phys
70 136 0.03 FCM T1-4, N0, M0
S-Phase

Oxford level 3b

Khoo et al., [194] 1999 The Prostate 42 62 0.035 FCM --
Pollack et al., [195] 1994 Cancer 76 40 0.05 FCM --

After brachytherapy

Oxford level 3b

Peters-Gee et al., [60] 1992 Cancer 51 52 <0.05 ICM --

After hormonal therapy

Oxford level 2b

Stege et al., [196] 1992 J Urol 67 >24 0.01 FCM  --

Oxford level 3b

Visakorpi et al., [67] 1991 Br J Cancer 60 120 0.0103 FCM --

After active surveillance

Oxford level 2b

Adolfsson et al., [197] 1990 J Urol 146 50 0.018 FCM Non-Progression. Therapy if progressed

Bold p-values refer to Cox multivariate regression analysis.

Böcking et al.Pathology Discovery  2014 2:7DOI : 10.7243/2052-7896-2-7